<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>李进医生团队 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-05T20:26:28+08:00</updated>
  <subtitle>科普宣传，患者教育。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>践行初心使命，彰显责任担当 | 秦叔逵、马军、李进教授共话肿瘤继续教育新动向</title>
    <updated>2020-11-05T14:29:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-05:/s/Q6dW9BG9n-_IwocXoWeWkA</id>
    <link href="https://mp.weixin.qq.com/s/Q6dW9BG9n-_IwocXoWeWkA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>周彩存教授：肺癌患者所关注的治疗相关疑问解答（上）</title>
    <updated>2020-11-04T15:05:54+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-04:/s/5a1CAK2nRu3pKsXYlzKY6Q</id>
    <link href="https://mp.weixin.qq.com/s/5a1CAK2nRu3pKsXYlzKY6Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>亚洲肿瘤联盟主席李进：从医生角度看中国抗癌药的投资方向</title>
    <updated>2020-11-03T15:26:52+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-03:/s/5j4dIFYNTwD3ML6s-_UsBA</id>
    <link href="https://mp.weixin.qq.com/s/5j4dIFYNTwD3ML6s-_UsBA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>抗癌路上 你我同在｜临床试验——肿瘤患者涅槃重生的希望</title>
    <updated>2020-11-02T21:22:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-02:/s/1ZOBRTs0SClsZNxtO0hC1g</id>
    <link href="https://mp.weixin.qq.com/s/1ZOBRTs0SClsZNxtO0hC1g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>​新一代微管抑制剂，引领化疗药物新突破</title>
    <updated>2020-10-31T11:37:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-31:/s/9lC3wR5Ovsxi2r9ceaKDKQ</id>
    <link href="https://mp.weixin.qq.com/s/9lC3wR5Ovsxi2r9ceaKDKQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FGFR4抑制剂与肿瘤</title>
    <updated>2020-10-31T11:37:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-31:/s/rnypZT3x3ZOC1ah6dkG3lQ</id>
    <link href="https://mp.weixin.qq.com/s/rnypZT3x3ZOC1ah6dkG3lQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>KEYNOTE-590吹响冲锋号——K药冲向食管癌治疗最前线</title>
    <updated>2020-10-29T15:34:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-29:/s/XlWfsOFJj3gTz8Bc9oq4tw</id>
    <link href="https://mp.weixin.qq.com/s/XlWfsOFJj3gTz8Bc9oq4tw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>殷咏梅教授：乳腺癌患者所关注的治疗相关疑问解答（下）</title>
    <updated>2020-10-27T16:39:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-27:/s/7dWB3IDOqHeKj939vOT0mg</id>
    <link href="https://mp.weixin.qq.com/s/7dWB3IDOqHeKj939vOT0mg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>免疫治疗的新型助燃剂</title>
    <updated>2020-10-22T16:43:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-22:/s/0ENgkAj9UURBTgXCPGbkHQ</id>
    <link href="https://mp.weixin.qq.com/s/0ENgkAj9UURBTgXCPGbkHQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>肿瘤临床试验中心正在招募受试者的项目更新10/22</title>
    <updated>2020-10-22T16:43:23+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-22:/s/C7L9kn8Q4rd8x4sXsvK2Mg</id>
    <link href="https://mp.weixin.qq.com/s/C7L9kn8Q4rd8x4sXsvK2Mg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>李进教授：从研究者角度看中国抗肿瘤药物研发创新之路</title>
    <updated>2020-10-21T16:58:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-21:/s/m1baF6wXdHBPBDN1-clEVg</id>
    <link href="https://mp.weixin.qq.com/s/m1baF6wXdHBPBDN1-clEVg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>40斤的“孕肚” ——需警惕的妇科杀手</title>
    <updated>2020-10-20T17:10:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-10-20:/s/Z-JJq3LOJtXoRy5a0nqDQA</id>
    <link href="https://mp.weixin.qq.com/s/Z-JJq3LOJtXoRy5a0nqDQA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>